MOUZIANE DEEB: Open Payments
NPI 1720102833 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 26 payments from 18 companies in 2025. Trend: 2023 $114 · 2024 $56 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Lilly USA, LLC | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
| Medtronic, Inc. | 1 | $35 |
| Janssen Biotech, Inc. | 1 | $28 |
| SOBI, INC | 1 | $24 |
| Geron Corporation | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $21 |
Products named: MYRISK, JARDIANCE, SYNCHROMEDII, MOUNJARO, DARZALEX, Doptelet, RYTELO, KEYTRUDA.
Industry payments across OK — which companies pay providers there.
